Analyst Price Target is $10.00
▲ +589.66% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Precigen in the last 3 months. The average price target is $10.00, with a high forecast of $14.00 and a low forecast of $6.00. The average price target represents a 589.66% upside from the last price of $1.45.
Current Consensus is
Hold
The current consensus among 3 contributing investment analysts is to hold stock in Precigen. This Hold consensus rating has held steady for over two years.
Precigen, Inc. operates as a discovery and clinical stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company, through its technologies, enables to find solutions for biotherapeutics. The company operates as an engine progressing a preclinical and clinical pipeline of therapies toward clinical proof-of-concept and commercialization. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Read More